Barclays Rates Natera (NTRA) buy, $260 Price Target

Barclays maintains its positive outlook on Natera, Inc. with a reiterated buy rating and a $260 price target, a 0.73% downside from the current price.

By EarningsIQ Research Desk · Published Jun 24, 2026, 11:01 AM EDT · Updated Jun 29, 2026, 6:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays rated Natera, Inc. ($NTRA) "buy" with a $260 price target on June 24, 2026.

Since the rating, $NTRA is up 6.3% after 1 week, up 0.8% after 1 month and up 51.3% to date (from the $259.97 close on Jun 24, 2026).

NTRA Natera, Inc.

$393.44 +71.93% year to date

Daily close · Oct 16, 2026

Key Points

Barclays reiterated its buy rating on Natera, Inc. (NTRA) with a $260 price target on June 24, 2026.
Barclays's $260 price target implies 0.73% downside from Natera, Inc.'s ($NTRA) current $261.91 share price.
Natera shares traded at $247.66 on Wednesday, with a market cap of $32.77 billion and a 52-week high of $256.36.
Insiders at Natera, including Executive Chairman Matthew Rabinowitz, sold shares in planned transactions in June 2026.

Get $NTRA trade alerts by text

We text you when insiders, Congress or big funds trade $NTRA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Natera, Inc. alert may contain errors. Disclosures

On June 24, 2026, Barclays reiterated its buy rating for Natera, Inc. (NasdaqGS: NTRA), setting a price target of $260. Analyst Luke Sergott maintained the positive outlook, signaling continued confidence in the company's prospects.

Analyst rating track record

Barclays vs. the S&P 500

YTD return +22.25% hypothetical

All-time return +39.40% S&P 500 +39.12%

vs. S&P 500 +0.28% ahead of the index

Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.

Natera, Inc. Stock Down 35.3%

Shares of Natera traded near $247.66 on Wednesday. The company, which operates in the healthcare sector focusing on diagnostics and research, boasts a market cap of approximately $32.77 billion. Despite not having a meaningful P/E ratio due to its unprofitability, Natera shows a beta of 1.544, indicating some volatility compared to the market. The stock's 52-week range spans from $131.81 to $256.36, with moving averages of $207.88 for 50 days and $206.57 for 200 days.

12-month forecast

$NTRA price target

Natera, Inc. daily closes and this analyst's $260 target. Not advice.

Recent Earnings

Natera reported revenues of about $2.5 billion, with a growth rate of 38.8%. However, the company has a net margin of -9% and a return on equity of -15%, reflecting ongoing challenges in achieving profitability. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at Natera, Inc.

Recently, several insiders at Natera have been selling shares. Executive Chairman Matthew Rabinowitz executed planned sales of 50,000 shares on both June 15 and June 12, 2026, at average prices of $214.91 and $214.03, respectively. Other insiders, including Sheena Jonathan and Gail Boxer Marcus, also sold shares in June.

Analysts Set New Price Targets

On June 24, 2026, Barclays maintained its buy rating with a $260 price target for Natera. Other analysts have also shown confidence in the stock. BTIG reiterated a buy rating with a $270 target on June 23, while RBC Capital reinstated its buy rating with a $275 target on June 12. Goldman Sachs began coverage with a hold rating and a $245 target on June 5. The consensus among 20 analysts remains a buy, with an average target price of $260.05.

About Natera, Inc.

Natera, Inc. is a diagnostics company headquartered in Austin, Texas. It develops and sells molecular testing services worldwide, including its flagship product Signatera, a personalized ctDNA blood test for monitoring cancer recurrence and treatment response. The company also offers a range of other tests for prenatal screening, hereditary cancer, and organ transplant rejection. Led by CEO Steven Leonard Chapman, Natera employs over 6,000 people.

Bottom Line

Barclays' reiteration of its buy rating for Natera, Inc. highlights enduring confidence in the company's market position and growth potential. Investors continue to monitor Natera's performance closely, especially given its significant presence in the diagnostics and research sector. As always, keep in mind that analyst ratings are based on past data and do not necessarily predict future performance.